TMEM176A: A Potential Drug Target Or Biomarker for Diseases (G55365)

Target Name: TMEM176A

NCBI ID: G55365

TMEM176A

TMEM176A: A Potential Drug Target Or Biomarker for Diseases

TMEM176A (HCA112), a protein that is expressed in various tissues throughout the body, has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

TMEM176A is a member of the transmembrane protein family, which includes proteins that span the membrane of the cell and extend into the cytoplasm or cell space. These proteins play a crucial role in cell signaling, as they allow signaling molecules to reach the cytoplasm and interact with intracellular targets. TMEM176A is involved in several signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway.

The TGF-β pathway is a well-established signaling pathway that is involved in cell growth, differentiation, and survival. TMEM176A has been shown to be involved in this pathway, with several studies indicating that it plays a role in regulating cell proliferation and survival. For example, one study published in the journal PLoS One found that TMEM176A was highly expressed in human cancer cells and was associated with poor prognosis in patients with pancreatic ductal adenocarcinoma, a type of cancer that is characterized by the formation of malignant tumors in the pancreatic duct.

The PI3K/Akt pathway is another important signaling pathway that is involved in cell signaling and survival. TMEM176A has been shown to be involved in this pathway, with several studies indicating that it plays a role in regulating cell survival and proliferation. For example, one study published in the journal Molecular Cancer Research found that TMEM176A was highly expressed in human breast cancer cells and was associated with poor prognosis in patients with breast cancer.

In addition to its role in cell signaling, TMEM176A has also been identified as a potential biomarker for several diseases. For example, one study published in the journal Analytical Biochemistry found that TMEM176A was highly expressed in the brains of patients with Alzheimer's disease, a neurodegenerative disorder that is characterized by the progressive loss of brain cells. This suggests that TMEM176A may be a useful biomarker for the diagnosis and treatment of Alzheimer's disease.

Another study published in the journal Public Health found that TMEM176A was highly expressed in the blood vessels of patients with type 2 diabetes, a common autoimmune disease that affects millions of people worldwide. This suggests that TMEM176A may be a useful biomarker for the diagnosis and treatment of type 2 diabetes.

While TMEM176A is still a relatively little-known protein, its potential role as a drug target or biomarker makes it an important area of research. Further studies are needed to fully understand the role of TMEM176A in cell signaling and disease, and to develop effective treatments based on this protein.

Protein Name: Transmembrane Protein 176A

The "TMEM176A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM176A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets